China was the second largest acute ischemic stroke (AIS) market, after the US, in 2017. The diagnosed incidence and prevalence of AIS in the country is slated to further increase due to rise in aging population and this presents an opportunity for stem cell therapy developers to penetrate the Chinese AIS market, says leading data and analytics company GlobalData.
According to the company’s survey, the diagnosed prevalence of AIS across the eight major markets (the 8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and China) will increase from an estimated 18.0 million ischemic stroke patients in 2017 to 19.4 million by 2027.
Dr. Edit Kovalcsik, Healthcare Analyst at GlobalData, says: “In China alone, the prevalent cases of AIS will grow from 5.3 million in 2017 to 8 million in 2027. As a result, China will experience the biggest market growth after the US, despite the lack of the new products launching in this market.”
However, the major barriers to the AIS market growth will be the availability of cheap and established anticoagulants such as warfarin, and the upcoming patent expiries of the branded non-vitamin K antagonist oral anticoagulants within 10 years, according to GlobalData analyst.
Dr. Kovalcsik adds: “Despite this, market sales will increase across the 8MM due to the increasing incidence and prevalence of AIS as well as the anticipated launches of novel, presumably highly priced, neuroprotective drugs and stem cell therapies.”
Despite the extended therapeutic time window for thrombolysis with Activase and implementation of endovascular treatment, scores of patients are still left with disabling neurological complications after a stroke. Poor neurological recovery following an AIS event is associated with great socioeconomic burden globally.
This reflects in the interview of key opinion leaders in China by GlobalData, in which after-stroke care has emerged as the biggest unmet need. Therefore there is need for drugs that could reduce disabilities and improve stroke outcomes, especially for those with chronic stroke requiring rehabilitation.
Kovalcsik concludes: “Organized after-stroke care is particularly poor in China, which results in a high proportion of AIS patients losing their ability to live independently. Developers have a great opportunity in the China AIS market to commercialize new products designed to improve stroke outcomes.”